APS Andy Peps Studio
Vials tend to hold more than the label (median +10.3%); 2 of 29 vials were more than 10% under.
For research use only. VendorVerify sells nothing and takes no money from vendors. No affiliate links, no coupon codes, no paid rankings. How scores work
Every vial we have on file
- Within ±5% / purity 99%+
- 5–20% under, overfilled / purity 95–99%
- Failed: over 20% under, over 50% over, empty or under 95% pure
Dose vs label
29 vials measured · 0 emptyPurity
27 vials measured- Median purity
- 99.70%
- across 27 vials
- Median dose vs label
- +10.3%
- across 29 vials; + means more than the label
- Failed vials
- 8.3%
- 5 of 32 vials; the rate weights each lab report equally and recent reports more, as the score does
- Lab reports
- 21
- Apr 30, 2025 to Aug 23, 2026
Labs: Freedom Diagnostics, Janoshik
Key facts
- VendorVerify holds third-party lab results for 32 APS vials from 21 lab reports, dated Apr 2025 to Aug 2026.
- 5 of 32 APS vials failed: empty, under 95% pure, more than 20% under the label or more than 50% over it.
- The median APS vial tested at 99.70% purity across 27 vials with a purity result.
- The median APS vial held +10.3% compared with its label across 29 vials where the lab measured the amount.
- Buyers have had 9 different compounds from APS lab tested.
- APS ranks #21 of 30 ranked vendors on the VendorVerify score.
- APS vials on file were tested by Freedom Diagnostics, Janoshik.
By peptide
| Peptide | Vials | Failed | Median purity | Median dose vs label | Dose vs label, −20% to +20% |
|---|---|---|---|---|---|
| Tirzepatide | 12 | 0 | 99.75% | +10.6% | |
| Retatrutide | 6 | 0 | 99.66% | +10.8% | |
| BPC-157 | 4 | 2 | 71.84% | +24.7% | |
| NAD+ | 4 | 3 | — | −26.8% | |
| CJC-1295 NoDAC | 2 | 0 | 98.92% | +1.7% | |
| GHK-Cu | 1 | 0 | 99.51% | — | — |
| Ipamorelin | 1 | 0 | 99.78% | −2.6% | |
| KLOW | 1 | 0 | — | +10.3% | |
| KPV | 1 | 0 | 99.68% | +27.6% |
Lab reports
One row per tested vial, newest first.
| Date | Peptide | Lab | Label | Measured | Dose vs label | Purity |
|---|---|---|---|---|---|---|
| Aug 23, 2026 | BPC-157Batch BPC10 CPIPTE | Freedom Diagnostics | 10 mg | 13.41 mg | +34.1% | 99.84% |
| Aug 20, 2026 | CJC-1295 NoDACBatch CJQY | Janoshik | 10 mg | 9.51 mg | −4.9% | 98.81% |
| Aug 10, 2026 | TirzepatideBatch PMQI | Janoshik | 10 mg | 11.31 mg | +13.1% | 99.08% |
| Aug 7, 2026 | GHK-CuBatch CUQY | Janoshik | — | 104.36 mg | — | 99.51% |
| Jul 28, 2026 | KPVBatch QWAR | Freedom Diagnostics | 10 mg | 12.76 mg | +27.6% | 99.68% |
| Jul 27, 2026 | BPC-157Batch PYQI - Blue Cap | Janoshik | — | 6.58 mg | — | 44.11% |
| Jul 27, 2026 | BPC-157Batch PYQI - Blue Cap | Janoshik | — | 6.74 mg | — | 44.07% |
| Jul 24, 2026 | RetatrutideBatch RWPTN | Janoshik | 20 mg | 20.2 mg | +1.0% | 99.74% |
| Jul 24, 2026 | RetatrutideBatch RWPTN | Janoshik | 20 mg | 20.26 mg | +1.3% | 99.72% |
| Jul 21, 2026 | KLOWBatch PMQA (reported per ingredient: GHK-Cu, KPV, TB-500, BPC-157) | Janoshik | 80 mg | 88.2 mg | +10.3% | — |
Other lab tests
Endotoxin, TFA, counterion and contaminant checks, as reported by the lab. They are shown for transparency and are not part of the score.
| Date | Peptide | Test | Result | Lab |
|---|---|---|---|---|
| Sep 29, 2026 | BPC-157Batch BPC10 CPIPTE | Endotoxin | <10 EU/Vial | Janoshik |
| Sep 2, 2026 | BB20Batch BBWY | Endotoxin | 80.210 EU/Vial. | Janoshik |
| Aug 25, 2026 | CJC/IPABatch CJC-1295/IPAMORELIN 5MG/5MG PUWN | Endotoxin | <10 EU/Vial | Janoshik |
| Aug 20, 2026 | RetatrutideBatch REPTN-1 R30 | Endotoxin | >1000 EU/Vial (1367.070 est.) | Janoshik |
| Aug 20, 2026 | CJC-1295 NoDACBatch CJQY | Endotoxin | 9.022 EU/Vial. | Janoshik |
| Aug 11, 2026 | TirzepatideBatch PMQI | Endotoxin | 1.166 EU/Vial | Janoshik |
| Aug 10, 2026 | GHK-CuBatch CUQY | Endotoxin | 17.477 EU/Vial. | Janoshik |
| Aug 4, 2026 | RetatrutideBatch R30 REPTN | Endotoxin | 1437.860 EU/Vial. | Janoshik |
| Jul 28, 2026 | KPVBatch QWAR | Endotoxin | Pass | Freedom Diagnostics |
| Jul 27, 2026 | BPC-157Batch PYQI - Blue Cap | Endotoxin | <10 EU/Vial (8.323 EU/Vial estimate) | Janoshik |
APS: common questions
Is APS legit?
We can't vouch for any vendor as a business, and we don't sell or recommend products. What we can show is what buyers' independent lab tests found: 5 of 32 APS vials on file failed, meaning they were empty, under 95% pure, more than 20% under the label or more than 50% over it. That places APS #21 of 30 ranked vendors, below market on our score. Results on file run from Apr 2025 to Aug 2026.
Has APS been third-party tested?
Yes. We hold results for 32 APS vials from 21 lab reports, tested by Freedom Diagnostics, Janoshik. Each result comes from a lab report a buyer paid for, not from a certificate the vendor supplied.
Are APS vials dosed correctly?
Across 29 vials where the lab measured the amount, the median APS vial held +10.3% compared with its label. 2 of 29 held more than 10% less than the label said.
How pure is APS?
The median APS vial tested at 99.70% purity across 27 vials with a purity result. We count anything under 95% as a failed vial, and a vial at 99.5% or higher gets full marks for purity.
Does APS pay to be listed or ranked?
No. VendorVerify sells nothing and takes no money from vendors. No affiliate links, no coupon codes, no paid rankings. A vendor's place comes only from lab results.
Will my APS vial match these results?
Not necessarily. A lab report describes the vials that were tested, and batches differ. A clean record lowers the odds of a bad vial but doesn't rule one out, which is why newer reports count for more in the score.
Vendor Reviews
Bought from this vendor?
Sign in to write a review. Every review comes from a verified phone number and a real purchase.